ABPI Chief Executive, Stephen Whitehead, comments on the publication of the Government’s Response to the Consultation on Amendments to the Statutory Scheme to Control the Prices of Branded Medicines, which are not covered by the Pharmaceutical Price Regulation Scheme (PPRS).
30 Jan 2015 Posted in News Release By Press Office
Stephen Whitehead said:
“The ABPI acknowledges the publication of the Response to the Consultation on Amendments to the Statutory Scheme and, as the recognised representative body for the biopharmaceutical industry, we welcomed the opportunity to respond to the consultation on behalf of industry.
“Whilst it is good news for now that no further price cuts will be imposed on branded medicines on top of the 15% imposed last year, I am concerned that there may be further cuts to come. The overall spend on medicines only represents 9.6% of total UK NHS spend. Furthermore the total medicine costs in the UK represent 0.9% of GDP compared to 1.2% average across other countries and our medicine prices remain low compared to other countries. It is important to recognise the value that the industry’s medicines bring to the NHS and most importantly to patients. The medicines spend in the UK is simply not a problem - but it is an easy target.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811